It has been recently reported that Sipuleucel-T or DNA based vaccine fosters the inflammatory response at the tumor site in prostate cancer patients and enhances the local expression of PD-1 and PD-L1, which suggests a rationale for combination therapy with ICI [37–39]. The gene discussed is CD274; the disease is prostate carcinoma.